This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram


Lavretsky, Helen, Siddarth, Prabha, Irwin, Michael R.


The American Journal Of Geriatric Psychiatry: Official Journal Of The American Association For Geriatric Psychiatry, Volume: 18, No.: 2, Pages.: 154-162

Year of Publication



Background: This study examined the potential of an antidepressant drug, escitalopram, to improve depression, resilience to stress, and quality of life in family dementia caregivers in a randomized placebo-controlled double-blinded trial.; Methods: Forty family caregivers (43-91 years of age, 25 children and 15 spouses; 26 women) who were taking care of their relatives with Alzheimer disease were randomized to receive either escitalopram 10 mg/day or placebo for 12 weeks. Severity of depression, resilience, burden, distress, quality of life, and severity of care-recipient’s cognitive and behavioral disturbances were assessed at baseline and over the course of the study. The Hamilton Depression Rating Scale scores at baseline ranged between 10 and 28. The groups were stratified by the diagnosis of major and minor depression.; Results: Most outcomes favored escitalopram over placebo. The severity of depression improved, and the remission rate was greater with the drug compared with placebo. Measures of anxiety, resilience, burden, and distress improved on escitalopram compared with placebo.; Discussion: Among caregivers, this small randomized controlled trial found that escitalopram use resulted in improvement in depression, resilience, burden and distress, and quality of life. Our results need to be confirmed in a larger sample.;

Bibtex Citation

@article{Lavretsky_2010, doi = {10.1097/jgp.0b013e3181beab1e}, url = {}, year = 2010, month = {feb}, publisher = {Elsevier {BV}}, volume = {18}, number = {2}, pages = {154--162}, author = {Helen Lavretsky and Prabha Siddarth and Michael R. Irwin}, title = {Improving Depression and Enhancing Resilience in Family Dementia Caregivers: A Pilot Randomized Placebo-Controlled Trial of Escitalopram}, journal = {The American Journal of Geriatric Psychiatry} }


aged, aged, 80 and over, antidepressant, anxiety, caregivers, citalopram, cognition, cost of illness, dementia, depression, double-blind method, drug effects, drug therapy, escitalopram, female, humans, male, middle aged, nursing, pilot projects, placebos, prevention & control, psychology, quality of life, remission induction, resilience psychological, stress, psychological, therapeutic use, treatment outcome

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Randomised Controlled Trial

Type of Outcomes

Carer Burden (instruments measuring burden), Carers’ Mental Health, Quality of Life of Carer

Type of Interventions

Intervention for Carers

Pharmaceutical Interventions

Antipsychotics and antidepressants

Carer Focussed Interventions